IDELALISIB PLUS ANTI‐CD20 USED SECOND LINE SHOWS IMPROVED PFS AND COMPARABLE SAFETY COMPARED TO LATER LINE THERAPY OF RELAPSED CLL. (12th June 2019) - Brown, J.R.; Chan, R.J.; Xing, G.; Bhargava, P.; Ruzicka, B.; O'Brien, S.M.